Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Gastroenterology. 2018 Oct 24;156(2):477–491.e1. doi: 10.1053/j.gastro.2018.08.065

Table 2.

Median OS (months) HR (95% CI)
First line
Lenvatinib vs. Sorafenib 13.6 vs. 12.3 0.92 (0.79 – 1.06)
Second line
Regorafenib vs. Placebo 10.6 vs. 7.8 0.63 (0.50 – 0.79)
*Nivolumab (Sor experienced: ESC/EXP) 15.0/15.6 NA
Ramucirumab vs. Placebo 8.5 vs. 7.3 0.710 (0.531–0.949)
Cabozantinib vs. Placebo 10.2 vs. 8.0 0.76 (0.63 – 0.92)
*

phase I/II trial